The Experts below are selected from a list of 246 Experts worldwide ranked by ideXlab platform
Andrew Campbell - One of the best experts on this subject based on the ideXlab platform.
-
Comparison of PSMA-HBED and PSMA-I&T as Diagnostic Agents in prostate carcinoma
European journal of nuclear medicine and molecular imaging, 2017Co-Authors: Michael Mccarthy, Tiffany Langton, Divesh Kumar, Andrew CampbellAbstract:Purpose Gallium(68)-labelled prostate-specific membrane antigen (PSMA) radiopharmaceuticals can be used to detect prostate cancer (PCa) cells due the their over expression of PSMA. The 68Ga HBED-PSMA (PSMA-HBED) ligand has been most widely used and can be considered the current gold standard Agent. Further PSMA ligands based on the DOTAGA and DOTA conjugates have more recently been developed. These Agents (PSMA-I&T and PSMA-617) have potential theranostic capabilities as they can be conjugated with therapeutic radioisotopes. In this study, we examine whether PSMA-I&T has comparative efficacy, such that it could replace PSMA-HBED as a Diagnostic Agent in prostate carcinoma.
Susan J. Mandel - One of the best experts on this subject based on the ideXlab platform.
-
Iodine-123 as a Diagnostic imaging Agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement
European Journal of Nuclear Medicine and Molecular Imaging, 2007Co-Authors: Muammer Urhan, Simin Dadparvar, Ayse Mavi, Mohamed Houseni, Wichana Chamroonrat, Abass Alavi, Susan J. MandelAbstract:Purpose Using^ 123I for Diagnostic purposes avoids the risk of stunning for subsequent radioiodine treatment and affords an excellent image quality. In this study we assessed the role of^ 123I in comparison with^ 131I post-treatment imaging in patients with thyroid cancer. Methods We compared a total of 292^ 123I scans with their corresponding post-treatment^ 131I images. Patients received a therapeutic dose of^ 131I following Diagnostic scanning with 50–111 MBq of^ 123I. All patients were in a hypothyroid state (>30 μIU/l) before radioiodine administration for either Diagnostic or therapeutic purposes. Results In 228 out of 263 patients with a positive Diagnostic scan,^ 123I whole-body scan findings were concordant with those of corresponding post-treatment^ 131I images (concordance rate 87%). However, there were 44 additional foci of abnormal uptake on post-treatment^ 131I scans in 22 discordant cases with no impact on therapeutic management of the patients. In 13 patients, there was at least one new site on post-treatment images that had been missed on pretreatment^ 123I images. Twenty-nine patients with a negative Diagnostic scan were treated with^ 131I owing to a high serum thyroglobulin level (range 11.3–480 ng/ml). Radioiodine uptake sites were seen in eight post-treatment scans. In 21 pairs of whole-body scans, both the pre- and the post-treatment scan were negative (concordance rate 72.4%). Conclusion ^123I scanning is comparable to high-dose^ 131I post-treatment imaging in thyroid carcinoma patients, and ^123I offers excellent image quality as a Diagnostic Agent. It avoids disadvantages such as stunning before treatment and delivery of a high radiation dose to patients.
Rakesh K Tekade - One of the best experts on this subject based on the ideXlab platform.
-
employment of enhanced permeability and retention effect epr nanoparticle based precision tools for targeting of therapeutic and Diagnostic Agent in cancer
Materials Science and Engineering: C, 2019Co-Authors: Dnyaneshwar Kalyane, Nidhi Raval, Rahul Maheshwari, Vishakha Tambe, Kiran Kalia, Rakesh K TekadeAbstract:Abstract In tumorous tissues, the absence of vasculature supportive tissues intimates the formation of leaky vessels and pores (100 nm to 2 μm in diameter) and the poor lymphatic system offers great opportunity to treat cancer and the phenomenon is known as Enhanced permeability and retention (EPR) effect. The trends in treating cancer by making use of EPR effect is increasing day by day and generate multitudes of possibility to design novel anticancer therapeutics. This review aimed to present various factors affecting the EPR effect along with important things to know about EPR effect such as tumor perfusion, lymphatic function, interstitial penetration, vascular permeability, nanoparticle retention etc. This manuscript expounds the current advances and cross-talks the developments made in the of EPR effect-based therapeutics in cancer therapy along with a transactional view of its current clinical and industrial aspects.
Abdallah Al Haj - One of the best experts on this subject based on the ideXlab platform.
-
123I Isotope as a Diagnostic Agent in the Follow-Up of Patients with Differentiated Thyroid Cancer: Comparison with Post 131I Therapy Whole Body Scanning
The Journal of clinical endocrinology and metabolism, 2001Co-Authors: Ali S. Alzahrani, Siema Bakheet, Majid Al Mandil, Alya Al-hajjaj, Abdulraouf Almahfouz, Abdallah Al HajAbstract:Radioactive iodine (131I) plays a major role in the diagnosis and management of differentiated thyroid cancer (DTC); however, data on the use of the 123I isotope in DTC are limited. We compared 238 Diagnostic whole body scans performed 24 h after oral ingestion of 185-555 MBq 123I with their corresponding 131I posttherapy whole body scans obtained 4-5 d after 131I therapy. We studied scans in 3 clinical situations: with the first 131I therapy, with the second 131I therapy, and in cases of elevated Tg and negative Diagnostic scan. One hundred and seventy-seven pairs were obtained with the first 131I therapy and showed complete concordance between pretreatment and posttreatment scans in 166 pairs (concordance rate, 93.8%). Six other posttreatment scans showed more foci in the thyroid bed than the pretreatment scans, but no evidence of uptake in new areas. Only 5 posttreatment scans showed foci in new locations: 3 in cervical lymph nodes (CLN), 1 in the lung, and 1 new bone metastasis in a patient with known skeletal metastases. With the second 131I therapy, 34 pairs were obtained and showed complete concordance in 28 pairs (concordance rate, 82.4%). Five discordant pairs showed additional foci in areas that were already positive on pretreatment scans. Only 1 posttreatment scan showed a new bone metastasis in a different site from the bone metastases that were seen on its corresponding pretreatment scan. Of 27 pairs of scans in patients with elevated Tg and negative pretreatment scans, 15 posttreatment scans remained negative, 6 posttreatment scans showed an uptake in the thyroid bed, and 3 other posttreatment scans showed lung uptake in patients whose computed tomography scans of the chest showed only bronchiectasis (in 2 patients) and lung scarring (in the third patient) without evidence of lung metastases. Three posttreatment scans showed definite uptake (in thyroid bed, thyroid bed and lung, and CLN) compared with their corresponding pretreatment scans, which were initially reported negative but were retrospectively thought to have had faint uptake. In 56 pretreatment scans, the 123I Diagnostic activity was 185 MBq, and the results showed complete concordance in 54 pairs. Two posttreatment scans showed additional uptake: 1 in the bone and 1 in CLN. These data suggest that pretreatment scanning using 123I is highly comparable to 131I posttreatment scanning and that 123I is an excellent Diagnostic Agent in DTC.
Michael Mccarthy - One of the best experts on this subject based on the ideXlab platform.
-
Comparison of PSMA-HBED and PSMA-I&T as Diagnostic Agents in prostate carcinoma
European journal of nuclear medicine and molecular imaging, 2017Co-Authors: Michael Mccarthy, Tiffany Langton, Divesh Kumar, Andrew CampbellAbstract:Purpose Gallium(68)-labelled prostate-specific membrane antigen (PSMA) radiopharmaceuticals can be used to detect prostate cancer (PCa) cells due the their over expression of PSMA. The 68Ga HBED-PSMA (PSMA-HBED) ligand has been most widely used and can be considered the current gold standard Agent. Further PSMA ligands based on the DOTAGA and DOTA conjugates have more recently been developed. These Agents (PSMA-I&T and PSMA-617) have potential theranostic capabilities as they can be conjugated with therapeutic radioisotopes. In this study, we examine whether PSMA-I&T has comparative efficacy, such that it could replace PSMA-HBED as a Diagnostic Agent in prostate carcinoma.